Lavipharm announced today, that it has entered into an Asset Purhase Agreement with Sanofi for the acquisition of the pharmaceutical product Flagyl  for the Greek market.

Commercialization of the product by Lavipharm is expected to take place upon completion of the relevant marketing authorization transfer, during Q2 of 2024. On an annual basis, the product has generated historical sales of approximately €1.4 million (Wholesale Prices) in Greece. The transaction will be financed by the company's own funds.

Telemaque Lavidas, Executive Board Member of Lavipharm, stated that "We are happy to have completed another acquisition just before we bid farewell to 2023. The addition of Flagyl, a renown and well-established antibiotic product to our portfolio, further solidifies our position in the pharmaceutical market."